ABZYME THERAPEUTICS LLC
- POTTSTOWN, PA 19464-3468
- abzymetx.com (company website, opens in a new tab)
- Partnership or Limited Liability Partnership
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 50 days
ABZYME THERAPEUTICS LLC’s registration expires on Jan 2, 2027. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About ABZYME THERAPEUTICS LLC
- Headquarters
- POTTSTOWN, PA 19464-3468
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIH2MLEFWV36N6
- CAGE62ES6
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 23 awards
- Total awarded
- $8,558,255
- By phase
- SBIR Phase I: 20
- SBIR Phase II: 3
- By agency
- Department of Health and Human Services: 18
- Department of Defense: 3
- Department of Agriculture: 2
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2024: 1
- 2023: 1
- 2021: 1
- 2019: 3
- 2018: 2
- 2017: 2
- 2016: 4
- 2015: 4
- 2014: 4
- 2011: 1
Awards (most recent first)
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,657,994
Mar 1, 2024 – Feb 28, 2026
Solicitation PA22-176 (2022) · Topic NEI
Novel immune-escape uricase for treatment of hyperuricemia
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $299,999
May 22, 2023 – Apr 30, 2024
Solicitation PA22-176 (2022) · Topic NIAID
Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $399,107
Sep 15, 2021 – Aug 31, 2022
Solicitation PA20-260 (2020) · Topic NINDS
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $299,989
Sep 1, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic NEI
Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $280,352
Aug 14, 2019 – Jul 31, 2020
Solicitation PA18-574 (2018) · Topic NIAID
Antibody Fragments to Improve HIV gp120 Protein Production
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $299,815
Solicitation year 2018 · Topic NIAID
Medical Countermeasure Development for Viral Induced Encephalitis Using Single DomainAntibodies
SBIR Phase II · Department of Defense (Office for Chemical and Biological Defense) · 2018 · $499,999
Nov 15, 2017 – Nov 14, 2019
Solicitation 2016.1 (2016) · Topic CBD161-004
Topic 373: Monoclonal Antibodies to RNA-modifications
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $299,999
Solicitation year 2017 · Topic NCI
Modular antibody engineering to overcome the blood brain barrier
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $236,646
Sep 25, 2017 – Aug 31, 2019
Solicitation PA16-302 (2016) · Topic 105
Development Of Arginine Linkage Specific Antibodies
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $224,926
Sep 15, 2017 – Aug 31, 2019
Solicitation PA16-302 (2016) · Topic 300
High throughput camelid antibody screening as a drug discovery platform
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,670,345
Sep 1, 2016 – Aug 31, 2019
Solicitation PA18-591 (2015) · Topic NIGMS
Novel approach for rapid generation of human antibodies to RNA-modifications
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $224,638
Jul 1, 2016 – Jun 30, 2018
Solicitation DA16-005 (2016) · Topic NIDA
Single domain antibodies as medical countermeasures for viral induced encephalitis
SBIR Phase I · Department of Defense (Office for Chemical and Biological Defense) · 2016 · $149,657
Jun 14, 2016 – Dec 13, 2016
Solicitation 2016.1 (2016) · Topic CBD161-004
Human monoclonal antibodies as countermeasures for T-2 mycotoxin
SBIR Phase I · Department of Defense (Office for Chemical and Biological Defense) · 2016 · $149,965
Dec 22, 2015 – Sep 30, 2016
Solicitation 2015.2 (2015) · Topic CBD152-003
High throughput approach for generating human monoclonal antibodies
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $224,799
Jul 1, 2015 – Jun 30, 2016
Solicitation PA14-071 (2015) · Topic 300
Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $264,747
Jun 1, 2015 – Nov 30, 2016
Solicitation PA16-019 (2016) · Topic 102
An Instant Estrogen Sensor for Poultry Gender Sorting Automation
SBIR Phase I · Department of Agriculture · 2015 · $99,943
Started Apr 23, 2015
Solicitation year 2015 · Topic 8.3
Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $224,935
Feb 3, 2015 – Jan 31, 2017
Solicitation PA14-071 (2015) · Topic N
Novel bispecific T cell engaging antibodies for treatment of Lyme disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $224,849
Solicitation PA13-234 (2014) · Topic NIAID · Research partner: Stub
Nanobodies for detecting and manipulating A to I editing enzymes and their modified RNA products
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $224,975
Solicitation DA15-001 (2014) · Topic NIDA · Research partner: Stub
High throughput camelid antibody screening as drug discovery platform
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $218,085
Solicitation PA13-088 (2014) · Topic NIGMS · Research partner: Stub
Low cost approach for production of sweet proteins as sugar substitutes
SBIR Phase I · Department of Agriculture · 2014 · $99,973
Solicitation year 2014 · Topic 8.5 · Research partner: Stub
Human Proteolytic Beta-Amyloid Specific Antibodies for Treatment of Alzheimers Di
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $282,519
Solicitation PA10-050 (2011) · Topic NIA · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with ABZYME THERAPEUTICS LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.